news uh that we've I guess been waiting for from Eli Liy. Got a look at the stock. Uh although we'll show you that Angelica Peeles that's here and joins us now, but uh as you're talking, we should take a quick look at the uh early morning action in the shares.But take it away. >> Yeah, that early morning action not good. The stock down about 6% right now and that's after we got this highly anticipated data on its obesity pill and clearly there's some disappointment.So let's go through the numbers. people lo ...

An experimental weight-loss pill from Eli Lilly helped people lose up to about 12% of their body weight, a new study found, potentially clearing the way for the drug to be on the market next year https://t.co/eihfsfp4I8 ...

Eli Lilly was nearly a $1 trillion company. Now it’s facing missed targets, tariff threats and investor doubts https://t.co/CW1FkuGaUS ...

Eli Lilly’s weight-loss drug underperformed in trials, sending its shares down and boosting Novo Nordisk’s stock https://t.co/UxkQixYEBD ...

Stock Performance - Lilly's stock experienced a decline in early trading [1] Pharmaceutical Products - Disappointing data on Lilly's new weight-loss pill was released [1] - The company experienced strong growth from its marketed obesity medicine [1]

August 7, 2025 For release: Immediately Refer to: Ashley Hennessey; gentry_ashley_jo@lilly.com; (317) 416-4363 (Media) Mike Czapar; czapar_michael_c@lilly.com; (317) 617-0983 (Investors) Lilly reports second-quarter 2025 financial results and raises guidance INDIANAPOLIS, August 7, 2025 - Eli Lilly and Company (NYSE: LLY) today announced its financial results for the second-quarter of 2025. "Lilly delivered another quarter of strong performance, achieving 38% year-over-year revenue growth driven by robust s ...

每经AI快讯，8月7日消息，礼来预计财年收入将达到600亿至620亿美元，此前预计为580亿至610亿美 元；礼来预计财年调整后每股收益为21.75美元至23.00美元，此前预计为20.78美元至22.28美元。 ...

Group 1 - The core point of the article is that Eli Lilly (LLY.US) reported a second-quarter adjusted earnings per share of $6.31, up from $3.92 in the same period last year [1] - The company has raised its full-year revenue guidance to between $60 billion and $62 billion, compared to the previous expectation of $58 billion to $61 billion [1]

Core Viewpoint - Eli Lilly reported a revenue of $15.56 billion for Q2 2025, representing a year-over-year growth of 38% [2] - The company has raised its full-year revenue guidance to between $60 billion and $62 billion, up from the previous estimate of $58 billion to $61 billion [2] Summary by Category - **Financial Performance** - Q2 2025 revenue reached $15.56 billion, marking a 38% increase compared to the same quarter last year [2] - Full-year revenue forecast adjusted to $60 billion to $62 billion, an increase from the prior range of $58 billion to $61 billion [2]

INDIANAPOLIS, Aug. 7, 2025 /PRNewswire/ --Eli Lilly and Company (NYSE: LLY) today announced its financial results for the second quarter of 2025. "Lilly delivered another quarter of strong performance, achieving 38% year-over-year revenue growth driven by robust sales of Zepbound and Mounjaro and sustained momentum across our key medicines," said David A. Ricks, Lilly chair and CEO. "Our pipeline continued to advance, highlighted by positive study results in oncology and cardiometabolic health—including Mou ...